Get the Stockscreener App
3.49
2.79%
-0.10
Pre-market:
3.50
0.010
+0.29%
Nevro Corp stock is traded at $3.49, with a volume of 543.82K.
It is down -2.79% in the last 24 hours and down -19.77% over the past month.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
See More
Previous Close:
$3.59
Open:
$3.5
24h Volume:
543.82K
Relative Volume:
1.10
Market Cap:
$130.78M
Revenue:
$425.17M
Net Income/Loss:
$-92.21M
P/E Ratio:
-1.358
EPS:
-2.57
Net Cash Flow:
$-67.42M
1W Performance:
-5.93%
1M Performance:
-19.77%
6M Performance:
-54.14%
1Y Performance:
-83.21%
1-Day Range:
$3.42
$3.59
1-Week Range:
$3.42
$3.985
52-Week Range:
$3.42
$21.00
Nevro Corp Stock (NVRO) Company Profile
Name
Nevro Corp
Sector
Industry
Phone
650-251-0005
Address
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Compare NVRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
3.49 | 130.78M | 425.17M | -92.21M | -67.42M | -2.57 |
|
ABT
Abbott Laboratories
|
114.25 | 198.16B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.95 | 141.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
364.10 | 138.80B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
82.68 | 106.02B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.15 | 43.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-24 | Initiated | Wells Fargo | Equal Weight |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-09-24 | Upgrade | Citigroup | Sell → Neutral |
| Aug-08-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Aug-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-07-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-07-24 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Feb-22-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-21-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| May-31-23 | Initiated | RBC Capital Mkts | Outperform |
| May-15-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Jan-17-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Downgrade | Piper Sandler | Neutral → Underweight |
| Dec-20-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Apr-13-22 | Resumed | Truist | Hold |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-09-21 | Downgrade | Truist | Buy → Hold |
| Aug-05-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-05-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-05-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-09-21 | Downgrade | Redburn | Buy → Neutral |
| Jul-06-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-02-21 | Initiated | Piper Sandler | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-08-20 | Upgrade | UBS | Sell → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Mar-20-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-20-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-28-18 | Initiated | UBS | Sell |
| Nov-07-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-06-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-06-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-19-18 | Downgrade | Goldman | Neutral → Sell |
| Jul-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-08-18 | Reiterated | Canaccord Genuity | Buy |
| May-08-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-08-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
View All
Nevro Corp Stock (NVRO) Latest News
Nevro stock plunges to 52-week low at $3.51 amid market challenges - Investing.com
Nevro stock plunges to 52-week low at $3.51 amid market challenges By Investing.com - Investing.com South Africa
Director Weatherman Elizabeth H was granted 5,325 shares, increasing direct ownership by 7% to 86,171 units (SEC Form 4) - Quantisnow
State Street Corp Has $4.21 Million Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
What Makes Nevro (NVRO) a New Buy Stock - Yahoo Finance
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - The Eastern Progress Online
Nevro price target lowered to $4.70 from $7 at Truist - Yahoo Finance
Where Nevro Stands With Analysts - Benzinga
Truist Financial Has Lowered Expectations for Nevro (NYSE:NVRO) Stock Price - MarketBeat
Nevro announces new inducement grants - Medical Buyer
Nevro Corp. (NYSE:NVRO) Receives $8.05 Consensus Target Price from Analysts - MarketBeat
Here's Why You Should Retain Nevro Stock In Your Portfolio Now - Barchart
Nevro shares price target cut, neutral stance held on potential By Investing.com - Investing.com South Africa
Nevro shares price target cut, neutral stance held on potential - Investing.com
Here's Why you Should Retain Nevro Stock in Your Portfolio Now - Nasdaq
Nevro Corp (NVRO) PT Lowered to $6 at Mizuho - StreetInsider.com
Nevro Corp's SWOT analysis: stock faces headwinds amid market challenges - Investing.com India
Nevro stock plunges to 52-week low, touches $3.95 By Investing.com - Investing.com South Africa
Nevro stock plunges to 52-week low, touches $3.95 - Investing.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 566,462 Shares of Nevro Corp. (NYSE:NVRO) - MarketBeat
Zacks.com featured highlights include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX - Yahoo Finance
Bet on 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance
Jacobs Levy Equity Management Inc. Buys 246,979 Shares of Nevro Corp. (NYSE:NVRO) - MarketBeat
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation - The Eastern Progress Online
Western Standard LLC Makes New $5.47 Million Investment in Nevro Corp. (NYSE:NVRO) - MarketBeat
Shay Capital LLC Increases Stake in Nevro Corp: A Strategic Move Amidst Financial Challenges - GuruFocus.com
Nevro Corp's SWOT analysis: stock faces headwinds amid SCS market challenges - Investing.com Canada
Nevro Corp's SWOT analysis: stock faces headwinds amid SCS market challenges By Investing.com - Investing.com South Africa
SVP, Chief Financial Officer Macleod Roderick H. covered exercise/tax liability with 816 shares, decreasing direct ownership by 0.61% to 133,118 units (SEC Form 4) - Quantisnow
SVP, Chief Operating Officer Christoforou Christofer covered exercise/tax liability with 583 shares, decreasing direct ownership by 0.42% to 138,399 units (SEC Form 4) - Quantisnow
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos - AOL
Morgan Stanley Maintains Positive MedTech Outlook… - Inkl
Morgan Stanley slashes Nevro stock target, flags SCS struggles and strategic challenges - Investing.com Canada
What Analysts Are Saying About Nevro Stock - Inkl
Morgan Stanley slashes Nevro stock target, flags SCS struggles and strategic challenges By Investing.com - Investing.com South Africa
Nevro (NYSE:NVRO) Downgraded to "Underweight" Rating by Morgan Stanley - MarketBeat
Morgan Stanley Downgrades Nevro Corp (NVRO) to Underweight - StreetInsider.com
Nevro downgraded to Underweight from Equal Weight at Morgan Stanley - TipRanks
Fred Alger Management LLC Has $93,000 Holdings in Nevro Corp. (NYSE:NVRO) - MarketBeat
Nevro (NVRO) Shares Outstanding (EOP) : 37.4 Mil (As of Sep. 2024) - GuruFocus.com
Engaged Capital LLC Has $13.66 Million Holdings in Nevro Corp. (NYSE:NVRO) - MarketBeat
NVRO Stock Declines Despite Positive Study Data of Nevro1 System - MSN
Nevro Corp. (NYSE:NVRO) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Nevro Corp Stock (NVRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):